Stephen J. Hoffman
Managing Director @ Skyline Ventures
United States
Stephen J. Hoffman is a Series B investor at Skyline Ventures in United States focused on Medical and Biotechnology. Stephen J. Hoffman - Chairman @ Apic Bio
- Total investments:
- 18
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Stephen J. Hoffman invests in
Stages Stephen J. Hoffman invests in
Countries Stephen J. Hoffman invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 4 (22%)
- Biotechnology 4 (22%)
- Health Care 3 (17%)
- Pharmaceutical 3 (17%)
- Life Science 1 (6%)
Stage
- Series B 4 (22%)
- Series C 3 (17%)
- Funding Round 2 (11%)
- Series A 1 (6%)
- Series D 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focusedon building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform. | $50M / Private Equity / Mar 10, 2015 | ||
| Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $45M / Series D / May 16, 2014 | ||
| Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalizedcancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines. | Series C / Oct 10, 2012 | ||
| Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focusedon building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform. | $22.5M / Feb 15, 2012 | ||
| Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focusedon building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform. | Series B / Feb 15, 2012 | ||
| Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $15.2M / Series C / Aug 12, 2011 | ||
| Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalizedcancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines. | $35M / Series B / Jan 03, 2011 | ||
| Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalizedcancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines. | $18.6M / Series B / Dec 01, 2009 | ||
| Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $50M / Series B / May 28, 2009 | ||
| Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium.Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline ofnew chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense. | $37M / Series C / Apr 30, 2008 | ||
| See all 18 investments → | |||
Co-Investors
About Skyline Ventures
Skyline Ventures, formed in 1997, is a nationally-known venture capital firm that specializes in investing in outstanding product-focused healthcare companies. Their areas of expertise include small molecule and protein therapeutics; medical devices; diagnostics; and technologies that facilitate drug discovery and life science research. They all have MD or PhD degrees, and hands-on operating experience in various start-up healthcare companies that later went public. As a result, they are known for the value they offer their companies, as board members and shareholders. They are also known for being fundamental, extremely patient investors. The days when momentum investing drove the public biotechnology markets are long gone, and they are glad that they are. The public markets demand data, not dreams. As a result, it is data that drives their decision process. In considering a new investment, they focus on whether there is adequate proof of principle to believe that the company's products will work. In therapeutics, for example, they look closely at whether the biochemistry, animal models and any human data make it more probable than average that the product will eventually prove to have an important therapeutic benefit. The size of the potential market and the quality of the management or founding team are critical in their evaluation as well. Skyline Ventures are value and return driven, more than driven by the stage of the investment. Most often they lead or co-lead a company's first or second institutional venture round, but have previously helped found companies and invested in PIPEs and leveraged buyouts. In October 2007, they completed raising Skyline V, which has $350 million in committed capital. They have approximately $800 million under management. They target investments of $15-35 million per portfolio company over the life of the company.
Skyline Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
John Freund
Founder & Managing Director
|
|||
Eric M Gordon
Founder & Partner
|
|||
|
Stephen J. Hoffman
Managing Director
|
|||
Yasunori Kaneko
Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Stephen J. Hoffman invest in?
Stephen J. Hoffman invests primarily in Medical, Biotechnology and Health Care startups, most often at Series B and Series C stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Stephen J. Hoffman?
Public channels for Stephen J. Hoffman include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Stephen J. Hoffman last invest?
The most recent investment recorded for Stephen J. Hoffman closed in Mar 2015. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
